Get the Stockscreener App
2.05
0.49%
-0.01
After Hours:
2.06
0.01
+0.49%
Annovis Bio Inc stock is traded at $2.05, with a volume of 769.65K.
It is down -0.49% in the last 24 hours and up +9.63% over the past month.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
See More
Previous Close:
$2.06
Open:
$2.09
24h Volume:
769.65K
Relative Volume:
0.95
Market Cap:
$71.03M
Revenue:
-
Net Income/Loss:
$-28.85M
P/E Ratio:
-1.4621
EPS:
-1.4021
Net Cash Flow:
$-25.62M
1W Performance:
-14.23%
1M Performance:
+9.63%
6M Performance:
-39.17%
1Y Performance:
+14.53%
1-Day Range:
$2.01
$2.139
1-Week Range:
$2.01
$2.4267
52-Week Range:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.05 | 71.37M | 0 | -28.85M | -25.62M | -1.4021 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Bio, Inc. Common Stock (NY: ANVS - The Chronicle-Journal
Annovis Bio, Inc. 1Q 2026: Net income $(17.61M), EPS $(0.63) — 10-Q Summary - TradingView
Rising R&D and going-concern risk at Annovis Bio (ANVS) as cash falls - Stock Titan
Annovis Bio (NYSE: ANVS) ramps R&D as Phase 3 Alzheimer’s trial advances - Stock Titan
Annovis Bio Releases Q1 2026 Financial Results - AlphaStreet
Annovis Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results - The Manila Times
ANVS Stock Price, Quote & Chart | ANNOVIS BIO (NYSE:ANVS) - ChartMill
TradingKey - TradingKey
Malvern company closes $10M offering to extend Alzheimer’s therapy testing - Pennsylvania Business Report -
ANVS Technical Analysis | Trend, Signals & Chart Patterns | ANNOVIS BIO (NYSE:ANVS) - ChartMill
ANVS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer’s at Fierce Biotech Week - MEXC
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 - mydailyrecord.com
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech ... - Herald and News
Number of shareholders of Annovis Bio Inc – FWB:07X - TradingView
Annovis Bio Publishes Phase 2/3 Alzheimer’s Trial Results - MyChesCo
Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of Research - TMX Newsfile
ANVS Earnings History & Surprises | EPS & Revenue Results | ANNOVIS BIO (NYSE:ANVS) - ChartMill
Annovis Bio | DEF 14A: Definitive information statements - Moomoo
Annovis Bio (ANVS) seeks approval to expand 2019 equity incentive plan at 2026 meeting - Stock Titan
Annovis Bio (ANVS) price target increased by 13.94% to 15.98 - MSN
Annovis Bio reports positive cognition data in early Alzheimer’s trial - Investing.com UK
Annovis Bio reports positive cognition results in early Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Bio reports positive cognition data in early Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio - The Manila Times
Annovis Bio reports positive cognition results in early Alzheimer’s trial - Investing.com
Annovis Bio, Inc. (NYSE:ANVS) Sees Significant Increase in Short Interest - MarketBeat
Annovis Bio Announces Transfer of Listing to the New York Stock Exchange - TMX Newsfile
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease - TMX Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022) - TMX Newsfile
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences - TMX Newsfile
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics - TMX Newsfile
Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference - TMX Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 - TMX Newsfile
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging - TMX Newsfile
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference - TMX Newsfile
Traders Buy Large Volume of Annovis Bio Call Options (NYSE:ANVS) - MarketBeat
Annovis Bio Price Target Maintained With a $17.00/Share by Canaccord Genuity - Moomoo
Aug Summary: Will Annovis Bio Inc stock recover after earnings2026 Chart Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Fed Watch: Can Annovis Bio Inc disrupt its industry2026 Spike Watch & Safe Capital Preservation Plans - baoquankhu1.vn
Retail Trends: Will Annovis Bio Inc benefit from seasonalityPortfolio Growth Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Annovis Bio raises $10M to fund Alzheimer’s drug trial By Investing.com - Investing.com Australia
Annovis Bio highlights buntanetap development in published article - MSN
Annovis secures financing for buntanetap’s NDA submission - The Pharma Letter
Annovis Bio raises $10M to fund Alzheimer’s drug trial - Investing.com
A $10M cash boost puts Annovis on track for an Alzheimer’s drug filing - Stock Titan
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):